{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-002131","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.918384+00:00","generated_at":"2026-05-24T01:45:16.455486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phio Pharma FY24 net loss $7.2M; PH-762 Phase 1b with complete responses; $12.1M raised","bullets":["Net loss for FY24 was $7.2M ($9.08/share), down from $10.8M ($46.76/share) in FY23.","Cash at Dec 31, 2024 was $5.4M; subsequent financings added net $6.8M, total $12.1M raised.","PH-762 Phase 1b: 3rd cohort fully enrolled; in cohort 2, 2 complete responses and 1 partial response out of 4 patients.","R&D expenses decreased 42% to $3.7M due to cost rationalization and termination of AgonOx agreement.","Total proceeds of $9.2M from registered direct offerings and $2.9M from warrant exercises."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-002131","json":"https://secwatch.observer/filing/0001683168-25-002131.json","markdown":"https://secwatch.observer/filing/0001683168-25-002131.md","text":"https://secwatch.observer/filing/0001683168-25-002131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825002131/0001683168-25-002131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825002131/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:45:16.455486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}